Vertex reveals FDA approval of New Drug Application for Suzetrigine for treating moderate-to-severe acute pain.

PepGen reports encouraging results from low-dose group in ongoing CONNECT1-EDO51 Phase 2 trial for treating Duchenne Muscular Dystrophy with PGN-EDO51.

Formycon AG announced the first enrollment in the Phase III "Lotus" study comparing FYB206/pembrolizumab with leading cancer drug Keytruda for safety and efficacy.

Celldex Therapeutics announces successful findings from Phase 2 trial of Barzolvolimab for chronic inducible urticaria.

Roche disclosed today that the European Commission has given the green light to Vabysmo® (faricimab) .

Galderma has successfully completed the European decentralized procedure, leading to a favorable decision for RelfydessTM.

Compugen has announced that the U.S. Food and Drug Administration has approved the investigational new drug application to begin a Phase 1 trial for COM503.

Alpha Cognition has reported that the U.S. Food and Drug Administration has given the green light to ZUNVEYL® (benzgalantamine).

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia.

CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer.

According to the agreement, Immunome has obtained exclusive rights to a collection of antibodies directed at an undisclosed target.

European Medicines Agency Rejects Eisai's Lecanemab for Alzheimer’s Treatment.